UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-KSB
[ X ] ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934
FOR THE YEAR ENDED DECEMBER 31, 1997
[ _ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM ______ TO ______
COMMISSION FILE NUMBER ____________________________
LIFESTREAM TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 82-0487965
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
515 PINE STREET, SUITE 200, SANDPOINT, IDAHO 83864
(Address of principal executive offices)
(208) 263-5433
(Registrant's telephone number, including area code)
SECURITIES REGISTERED UNDER SECTION 12(b) OF THE EXCHANGE ACT:
TITLE OF EACH CLASS NAME OF EACH EXCHANGE ON WHICH REGISTERED
- ------------------- -----------------------------------------
SECURITIES REGISTERED UNDER SECTION 12(g) OF THE EXCHANGE ACT:
COMMON STOCK, PAR VALUE OF $0.001
---------------------------------
TITLE OF CLASS
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or shorter period
that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.
Yes [ X ] No [ _ ]
Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best off registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. [ ]
State issuer's revenues for its most recent fiscal year. $0.00
The aggregate market value of the voting and non-voting common equity held by
non-affiliates computed by reference to the closing price of $4.06 at which the
common equity was sold, as of May 4, 1998 was $17,545,136
The number of shares outstanding of the registrant's common stock as of May 4,
1998 was 8,502,829
1
<PAGE>
<TABLE>
<CAPTION>
INDEX
- -----
<S> <C>
PART I
Item 1. Description of Business 3
Item 2. Description of Property 11
Item 3. Legal Proceedings 11
Item 4. Submission of Matters to a Vote of Security Holders 11
PART II
Item 5. Market for Common Equity and Related Stockholder Matters 12
Item 6. Management's Discussion and Analysis or Plan of Operation 13
Item 7. Financial Statements F-1 to F-23
Item 8. Change in and Disagreements with Accountants 16
PART III
Item 9. Compliance with Section 16(a) of the Exchange Act 17
Item 10. Executive Compensation 19
Item 11. Security Ownership of Certain Beneficial Owners and Management 20
Item 12. Certain Relationships and Related Transactions 21
Item 13. Exhibits and Reports on Form 8-K 22
Signatures 23
</TABLE>
2
<PAGE>
PART I
Item 1. Description of Business.
Overview
- --------
Except for the historical information contained herein, the following discussion
contains forward-looking statements that involve risks and uncertainties. The
Company's actual results could differ materially from those discussed herein.
Factors that could cause or contribute to such differences include, but are not
limited to, those matters identified in this section under the caption "risk
factors".
Lifestream Technologies, Inc. (the "Company" or "Lifestream"), which was
formerly Utah Coal and Chemicals Corporation, is a Nevada corporation,
reorganized on February 11, 1994 with its current address at 515 Pine Street,
Suite 200, Sandpoint, Idaho 83864. Lifestream is a development stage enterprise,
having reported no revenues to date, formed to develop, manufacture and market a
line of health diagnostic instruments to domestic and international markets.
Lifestream's initial product offering will be the CholestronTM, a hand held
instrument that measures cholesterol levels in the blood with medical laboratory
accuracy in under five minutes. It is used in conjunction with a disposable
dry-chemistry test strip. The Company has recently signed a manufacturing
agreement with Boehringer Mannheim, whereby Boehringer Mannheim will supply to
the Company the dry chemistry test strips and invitro diagnostic optic hardware
used by the CholestronTM. This combination of Boehringer Mannheim's proven
production capabilities and Lifestream's marketing strategies will set the
foundations for the Company's first product entry.
The CholestronTM will initially monitor only total cholesterol levels, but the
Company plans subsequent introductions of systems and disposable test strips
which can also make readings of HDL (high-density lipoprotein) cholesterol,
triglycerides, LDL (low-density lipoprotein) cholesterol levels, and possible
glucose in one instrument.
Lifestream plans to introduce the CholestronTM "professional product" to the
market through health professionals, including physicians, HMO's and
wellness/lifestyle educators (work site health promotion programs). The
physician sites, potentially the largest market segment for the "professional
product", it is estimated that up to 350 million tests are performed annually.
The CholestronTM will cut the usual 24 to 48 hour waiting period down to a
matter of minutes and is expected to reduce the costs involved in such a test.
Initially, the Company will distribute its products to pharmaceutical companies
who sell cholesterol lowering drugs, and pharmacists offering on-site testing to
their customers. The "consumer product", introduced after the successful
implementation of our professional marketing strategy, will be geared toward
patients with high cholesterol levels who need to monitor their progress on a
cholesterol-reducing program.
The Company believes the CholestronTM professional instrument offers important
education features absent in competing technologies. Using the CholestronTM's
keypad, the user will be able to enter risk factors associated with heart
health. The device uses these factors to calculate the patients "biological"
age, i.e. a measure of how the patient's heart health compares to others. By
changing parameters, a patient can learn how his or her biological age will
improve by changing certain lifestyles, such as quitting smoking or exercising.
A key part of this system is the CholestronTM "smart card", holding up to 75
bytes of information, which will contain the patients cholesterol readings and
other risk factors downloaded from the CholestronTM meter. This information is
then transferred to the physician's office computer via the "smart card" to
provide the patient's risk profile.
3
<PAGE>
By accessing Lifestream's secured intranet program created jointly with Secured
Interactive Technologies, Inc. (formerly Interactive Health Evaluation Systems,
Inc.), a health information software company, the physician can merge the "smart
card" patient information with the latest health research to create a "Personal
Health Evaluation Program" for each patient. This personalized program can then
be printed out and reviewed with the patient and the physician within a couple
of minutes. It can be continually updated, providing physicians with a
state-of-the-art tool to evoke behavioral change.
The Company believes this approach to fighting and monitoring high cholesterol
is what sets the CholestronTM apart from its competitors. The Company expects
competition from several companies, including those using "singe use"
cholesterol (screening) test strips and those developing an instrument/strip for
monitoring and diagnostics. The Company believes that no competitor to date has
introduced a monitoring product into the U.S. over-the-counter market (retail),
or met the Company's targeted price range for the professional.
In April 1998, the Company completed the required clinical studies for the
Cholestron(TM) unit. Upon successful completion of those studies, the Company
filed a 510(k) notification with the Federal Drug Administration ("FDA"). It is
the Company's belief that the FDA's approval will be successfully obtained by
July 1998. Once the approval has been received, it is the Company's intention to
immediately commence with commercial production of the CholestronTM product.
Corporate Formation:
- --------------------
Lifestream Development Partners was organized in 1989 as a general partnership
for the purpose of developing the Cholestron lipid monitor device. The primary
purpose of the original partnership was to engage in product/chemistry research
and development, purchase production and exclusive distribution rights to
certain technology and to engage in various pre-marketing and pre-production
programs to make a transition into the next phase of corporate development. The
original three investors in the project selected a partnership as a business
entity in order to realize certain tax advantages. During this first phase of
research and development and technology acquisition, the partnership was
capitalized for $2,500,000 by the three investors.
For the second phase of business, the principals of the Lifestream general
partnership organized Lifestream Diagnostics, Inc., as a Nevada corporation on
June 1, 1992. On August 7, 1992, the partnership transferred its net assets,
consisting primarily of purchased patent rights to the dry strip chemistry, to
the Company in exchange for 3,327,000 shares of the Company's common stock.
On February 11, 1994, the Company entered into a plan of reorganization (with
shareholders consent and board approval) whereby Lifestream executed an exchange
agreement to be acquired by Utah Coal & Chemical ("UTCC"), as a subsidiary
corporation. Prior to the acquisition of Lifestream by UTCC, UTCC had 3,295,650
shares of common stock issued and outstanding that were owned by 685 registered
shareholders. The 3,295,650 shares were reverse split on a basis of 4 to 1,
resulting in 823,913 shares outstanding at the time of acquisition. Lifestream
was acquired in exchange for the issuance of 4,200,000 shares of restricted
common stock. On a post acquisition basis, the total outstanding shares were
5,023,913. Simultaneously, UTCC changed it's name to Lifestream Technologies,
Inc.
4
<PAGE>
Industry Overview and Product Technology Summary:
- ------------------------------------------------
Approximately 60 million Americans have been diagnosed with cholesterol levels
higher than 200 mg/Dl, the level established by numerous national health
agencies as borderline-high. Many millions of additional people have yet to test
blood cholesterol levels, although a decade long public health campaign has made
them aware of the importance of knowing their cholesterol levels and initiating
health and dietary programs to reduce high counts.
Using standard centrifugation, heretofore, cholesterol testing has required
large samples of whole blood for use in separating the red blood cells from
serum/plasma with results in 24 to 48 hours. Such separation is vital to assure
proper color change during cholesterol testing; only the clear plasma is used
for reflectance measurement. In addition, today's machines must also be
presented with exact amounts of whole blood. Even the machines that are now
using chemistry/strip technology continue to require relatively large amounts of
whole blood, and their costs are in excess of $5,000. The tests also take a
minimum of four to five minutes, in addition to the blood drawing and
centrifugation, to determine results.
It is the belief of management of the Company that there is a large need in the
professional market for convenient on-site testing, with immediate results. The
Company further believes that multiple tests, a benefit in baseline testing,
coupled with a life style risk analysis program, provides a market demand for a
new product.
To exploit these anticipated opportunities, the Company assembled a core group
of engineering, analytical chemistry, manufacturing and marketing talent who
collectively possess decades of experience in development of opto-electronic
integrated measuring equipment and consumer dedicated specialized operational
software. This group has developed a cholesterol diagnostic and monitoring
system comprised of dry chemistry reagent test strip technology and a portable,
analytical instrument for both professional and home markets. The Cholestron
system also meets safety, reliability, accuracy and precision requirements
consistent with medical laboratory units.
The Cholestron(TM) unit is relatively small having dimensions of 6.5" x 4.5" x
2" and an approximate weight of one pound. The device utilizes test strips which
are inserted into the Cholestron device after a single blood drop is placed on
the strip. The "user friendly" instrument incorporates a keypad which is used to
turn on the instrument, recalibrate it by use of a code which is unique to each
batch of chemistry strips and on the "professional product" to enter in the
thirteen risk factors identified as indicators of heart health. There is also an
easy-to-read liquid crystal display (LCD) on the face of the instrument on which
the test results number is displayed. The third visible item on the face of the
unit is the optical head, into which the dry chemistry test strip is inserted to
begin the test.
Lifestream's CholestronTM technology is differentiated from current cholesterol
measuring technology by accurate, dry chemistry, in-vitro diagnostics resulting
from a single finger stick drop of blood. The quantitative cholesterol result is
obtained in one minute and does not require an exact amount of whole blood. The
structure of the technology consists of three (3) layers of membranes which as a
system: a)transport the whole blood sample tangentially (cross-flow), b) provide
filtration/separation with multiple reaction and cross-flow filtration, and c)
present "on-line" chemical reaction on contact of serum with enzyme treated
membranes. The resulting color change is "read" by the instrument's photometry
system, and then converted electronically to a cholesterol digital read-out
which is displayed on the liquid crystal display screen of the instrument. The
professional product will also include a cardiac risk calculator, allowing the
professional operator to determine the cardiac condition of the patient from ten
plus different cardiac risk factors (based on the Framingham study).
5
<PAGE>
In order to facilitate a cholesterol measurement on the Cholestron,TM the
operator prick's the finger, using a reusable lance device, complete with a
disposable lancet. Then a drop of blood is placed on the chemical strip and the
strip inserted into an opening of the optical head on the face of the unit. In
approximately one minute the cholesterol number (which is actually the
milligrams of cholesterol per deciliter of blood) will display on the screen.
The Company believes that the unit is easier to use, is more accurate and is
faster than any other system on the market today. It will initially retail for
approximately $250 for the professional model and $130 for the consumer model,
which the Company believes to be lower than any other competitive system.
If the introduction of the CholestronTM system is successful, the Company will
proceed with development of a follow-on product which will test and display not
only total cholesterol but make a separation of HDL (high-density lipoprotein)
the so-called "good" cholesterol and LDL (low density lipoprotein) cholesterol,
as well as measure the triglycerides (or amount of fat) in the sample. Other
products in development include devices which perform multiple tests on a blood
sample, such as blood glucose levels, as well as cholesterol amounts.
Status of Publicly Announced Product Development:
- ------------------------------------------------
Production of the CholestronTM Device
There are three components to the CholestronTM device. The Cholestron
instrument, the test strips and supply kit. The Company intends to manufacture
the handheld CholestronTM device. To that end the Company is pursuing the
execution of a lease agreement for a facility located in Post Falls, Idaho.
Lifestream anticipates employing approximately 10 people to assemble the device
and package it for final retail.
Separately, the test strip and invitro diagnostic optic hardware will be
manufactured by Boehringer Mannheim, a leader in the field of medical
diagnostics. Lifestream signed a license and manufacturing supply agreement with
Boehringer Manneheim in November 1997. This agreement provides for immediate
production capacity. Boehringer Mannheim's successful and proven technology will
be integrated into Lifestream's device. In addition, this agreement eliminates
an estimated $2 to $10 million capital requirement that would have been required
if Lifestream were to pursue its own production of its patented chemistry.
Lifestream can still commercialize its own chemistry, and at a later date, the
Company intends to pursue the enhancement of its technology to include the
ability to read HDL (high-density lipoprotein) cholesterol, Triglycerides, LDL
(low-density lipoprotein) cholesterol, and glucose.
Once the test strips are produced, the packaged test strips will be shipped to
the Company's production facility for final quality assurance inspection and
packaging with the instrument for shipment to customers (each instrument is sold
with one box of six disposable test strips). The test strips will also be
packaged in different configurations for sale to instrument owners to replenish
strips used in testing.
6
<PAGE>
Competition:
- -----------
Because of the potential size of the market for quick, inexpensive, portable
methods of cholesterol testing, there are several companies, both established
and new, and many of which may have substantial greater financial resources than
Lifestream - working on products competitive to the CholestronTM system.
Competition can be broken into two groups, those firms pursuing "single use"
cholesterol (Screening) tests and those developing an instrument/strip
(Diagnostic/Monitoring) instrument based tests. A summary of what is known by
the Company about potential competitors in both groups is listed below:
Consumer Market Disposable Testing - "Single Use"
- ------------------------------------------------
Several companies have introduced or are working on disposable cholesterol
testing cards. These are very basic tests where the user takes a blood sample,
drops it on the test card and visually compares the resulting color change or
color movement (similar to a thermometer) of the sample to a color chart. These
tests require user interpretation and are semi-quantitative, which are usually
not acceptable standards for the professional market, limiting its use for
screening purposes. Specific accuracy is not available, cholesterol counts are
given in "ranges" (e.g. like 150-200) and the additional issues of user color
blindness or printing accuracy of the color chart must be considered. The
Company feels that these tests will not provide competition for the segment of
the consumer marketplace which is interested in serious cholesterol level
testing and maintenance. The Company believes that if given a choice between
on-site pharmacist testing at a lower cost in just one minute and spending $15
to perform the test at home, a large portion of consumers will choose the
former. It is also clear that those consumers who wish to monitor a cholesterol
lowering program will not choose to spend $15 for each single use test when an
instrument for multiple testing is faster and less expensive. Specific
competitors include Chemtrak whose product is similar to Crystal Diagnostics,
and is expected to have problems in the professional market due to their 15
minute results. This product is also a non-instrument, semi-quantitative test,
is dependent on user-interpretation, and is used primarily for screening. First
and only test approved by the FDA for consumer sales. Expected price per test:
$10-15
Instrument/Disposable Strip - Multiple Use Instruments
- ------------------------------------------------------
Companies currently shipping product in this market segment are focused solely
on the professional market. The barriers to entering the consumer market have
been, and continue to be, cost of the instrument and the fact that a large and
exact quantity of blood is required for the test.
Specific competitors are as follows:
Boehringer Mannheim Diagnostics - A division of Boehringer-Mannheim GmbH,
currently markets its "Reflotron" to the professional market. The Reflotron, a
$5,000 table-top analyzer, is the dominant product in the field, but requires an
exact amount of blood measured with a glass pipette (a drop is not sufficient).
This is a 4-minute test.
Cholestech - A private company founded to develop a diagnostic instrument for
the professional markets. Its business plan calls for the instrument, which
should test whole cholesterol as well as HDL and LDL levels, to sell at
approximately $2,000 per unit. Also, a review of the instrument shows that it
requires a large, exact amount of blood for testing, which may not be practical
for office use.
7
<PAGE>
Patents and Proprietary Instruments:
- -----------------------------------
The Company has one patent which was issued August 4, 1992. The patent covers
the invention of direct measurement of HDL cholesterol with dry chemistry
strips. Additionally, the Company has four patents which are applied for and
pending (see below).
<TABLE>
<CAPTION>
Patent Title Status
- ------------ ------
<S> <C>
1. Direct Measurement of HDL Cholesterol Via Dry Chemistry Strips Issued 8-4-92
2. New Evenly Dispersed Stabilized Enzyme System Comprises Applied and Pending
Enzymes Entrapped in Pores of Solid Microporous Carrier
3. Obtaining and Analyzing Plasma Separation Membrane and Applied and Pending
Plasma Collecting Test Membrane
4. Device for Separation of Plasma from Blood and Determination Applied and Pending
of Analyses(S)
5. Device and Method for Separation of Fluid Components Applied and Pending
</TABLE>
Governmental Regulation:
- -----------------------
The Company's products are under the regulation of the United States Food and
Drug Administration (FDA). Prior to any marketing of these devices, the Company
must first obtain pre-clearance from the FDA, either through the notification
("510(k) Notification") process or the pre-market approval application ("PMA")
process.
Lifestream has filed a 510(k) notification for the CholestronTM system with FDA.
Because it is the Company's opinion that the product is "substantially
equivalent" to other products being marketed, specifically, blood glucose
monitoring devices, the more lengthy PMA is not required from the FDA. FDA
approval is expected by July 1998.
Completion of the 510(k) notification satisfies safety and effectiveness
requirements for sales to or through professionals. Additional labeling features
should satisfy retail marketing requirements. Although the Company expects
imminent 510(k) notification, it cannot be guaranteed. In this regard,
Lifestream is pursuing interim sales opportunities in Canada, Australia and
Europe should U.S. sales be delayed. Based on preliminary results and
interaction with the FDA, the Company believes this objective can be achieved.
Research and Development Activities:
- -----------------------------------
During the years ended December 31, 1997 and 1996, the Company has expended
funds on research and development activities of approximately $107,000 and
$32,000. In addition, a significant portion of all other operating expense
amounts incurred were indirectly related to product development. It is expected
that the Company will continue to expend significant amounts for research and
development for the foreseeable future periods.
8
<PAGE>
Company Employees:
- -----------------
As of May 1, 1998, the Company had five full time employees. These employees are
involved with research and development, accounting, and other administrative
matters necessary to bring both the Company and the CholestronTM Device to a
position where the manufacture and marketing of this product can begin. It is
the expectation of the Company that before the completion of the second quarter
of 1998, the Company will have a total staff of ten to twelve employees, some of
which will be involved in the pre-production phase in anticipation of FDA market
approval.
Risk Factors:
- ------------
This section summarizes certain risks that should be considered by stockholders
and prospective investors in the Company.
Development Stage Enterprise
The Company has incurred losses since inception and remains in the development
stage. As of December 31, 1997, the Company's accumulated deficit was
$2,405,295. Until such time as governmental approval has been obtained, and
finalization of the product has occurred, it is expected that these losses will
continue. There can be no assurance that the Company will achieve profitability
in 1998, or if achieved, can be sustained on an ongoing basis. As a result of
these factors, the Company's independent certified public accountants included
an explanatory paragraph in their report on the Company's 1997 consolidated
financial statements which expressed substantial doubt about the Company's
ability to continue as a going concern.
Dependence on Key Personnel
The Company is dependent on its Chief Executive Officer, the loss of whose
services could have a material adverse impact to the business. In 1998, the
Company obtained a key man life insurance policy for the Chief Executive
Officer. In addition, as the Company approaches the point in time where product
market entrance can occur, the ability to attract, recruit and retain qualified
personnel will be important to the ultimate success of the Company. There can be
no assurances that the Company will be successful in these endeavors.
Market Acceptance
The Company has been involved in the development of a product for which no
revenues have yet to have been generated. There is no assurance that this
product will receive a market acceptance at such a level that both profitable
items can be sold, and in such quantities, as to provide for financial success
for the Company.
Medical Industry
The medical industry is one in which rapid technological change has occurred in
the past several years. Additionally, certain industry trends point to further
competitiveness and changes in the manner in which products will be delivered to
the consumer. There can be no assurances that the Company's product will not
become rapidly obsolete. Additionally, there can be no assurance that
competitive pressures may not adversely impact, in a material nature, the
delivery of such a product.
Volatility of Stock Price
The market price of the shares of the Company's common stock, like that of other
development stage enterprises, has been highly volatile. Factors including, but
not limited to, those items mentioned herein can be expected to produce
continued significant fluctuations in the market price.
9
<PAGE>
Government Regulation
Lifestream's CholestronTM Device will be regulated under the 1976 Medical Device
Amendments to the Food, Drug and Cosmetic Act. The Device may be classified as a
Class I or Class II device, which could require the submission of information to
substantiate label claims prior to marketing. To date the Company has submitted
the required 510(k) notification, however, there can be no assurance that FDA
approval will be obtained. Additionally, there can be no assurance that the FDA
will not require further information or studies which could further delay market
introduction.
Manufacturing Experience
The Company has not commercially introduced any products. Prior to the
introduction of the CholestronTM Device, the Company must select and qualify its
sources of supply of key components and be able to manufacture in compliance
with regulatory requirements, including Good Manufacturing Guidelines, in
sufficient quantity, with appropriate quality and at acceptable costs. At
present the Company's manufacturing capabilities are limited to producing
prototypes and materials for evaluation. The Company will need to expand these
operations to achieve commercial production levels. In addition, the Company
will need to develop the management infrastructure necessary to manage its
manufacturing operations. There can be no assurance that the Company will be
able to make the transition to commercial production successfully, or, to the
extent it chooses to subcontract its manufacturing, that it will be able to
reach agreement on terms which are favorable to the Company.
Marketing Experience
While certain members of the Company's management have relevant marketing
experience, Lifestream has no experience marketing its products directly to end
users. When and if the Company obtains the necessary regulatory approval to
commercialize its products, the Company intends to use third party medical
product distributors to market to alternate care sites. In the event that the
Company does not enter into third party distribution agreements for its
products, significant additional capital expenditures and management resources
will be required to develop and expend its direct sales force. While the Company
has identified potential domestic distributors, no formal distribution contracts
have been executed. There can be no assurance that the Company will be able to
establish such a sales force or enter into such third party distribution
agreements to gain market acceptance for its products.
Competition
The consumer retail and physician office markets are expected to attract a large
number of competitors, many of which may have substantial greater resources than
Lifestream. There can be no assurance that the Company's products will be
competitive with existing or future products, or that the Company will be able
to establish and maintain a profitable price structure for its products.
10
<PAGE>
Item 2. Description of Property.
All of the Company's operations are conducted from its leased office facility
located in Sandpoint, Idaho. The lease agreement terminates on July 31, 2000.
The monthly lease payment is currently $555 and increases annually by the
percentage increase of the Consumer Price Index.
As regulatory approval for the Cholestron TM product is expected to be received
by the Company by July 1998, the Company executed a lease agreement for a
production facility in located in Post Falls, Idaho, in May 1998. The Company
expects to take possession of this 6,500 square foot facility in June 1998, and
immediately begin preparation for a preproduction runs of the CholestronTM
product.
The Company does not currently make any investments in real estate or interests
in real estate, including real estate mortgages or securities issued by persons
primarily engaged in real estate activities, and the Company does not intend to
make such investments in the future.
Item 3. Legal Proceedings.
No matters for inclusion herein.
Item 4. Submission of Matters to a Vote of Security Holders.
No matters for inclusion herein.
11
<PAGE>
PART II.
Item 5. Market for Common Equity and Related Stockholder Matters
The Company's Common Stock trades in the NASDAQ bulletin board market (NASDAQ
BB.LFST). The following table shows the quarterly high and low bid prices for
1996, 1997 and 1998 as reported by the National Quotations Bureau Incorporated.
These prices reflect inter-dealer quotations without adjustments for retail
markup, markdown or commission, and do not necessarily represent actual
transactions.
Year Period High Low
---- ------ ---- ---
1996 First Quarter $1.50 $ .75
Second Quarter $1.25 $ .97
Third Quarter $ .63 $ .13
Fourth Quarter $1.00 $ .37
1997 First Quarter $1.03 $ .43
Second Quarter $ .81 $ .43
Third Quarter $1.06 $ .35
Fourth Quarter $1.59 $ .59
1998 First Quarter $1.00 $ .68
At May 4, 1998 there were approximately 750 holders of record of the Company's
Common Stock.
The Company has never and has no intentions at this time to declare dividends on
its common stock. The Company presently intends to retain future earnings, if
any, to finance the expansion of its business. The future dividend policy will
depend on the Company's earnings, capital requirements, expansion plans,
financial condition and other relevant factors.
12
<PAGE>
Item 6. Management's Discussion and Analysis or Plan of Operation
Except for the historical information contained herein, the following discussion
contains forward-looking statements that involve risks and uncertainties. The
Company's actual results could differ materially from those discussed herein.
Factors that could cause or contribute to such differences include, but are not
limited to, those matters discussed previously under the heading Business and
Risk Factors.
Results of Operations, years ended December 31, 1997 and 1996
The Company is a development stage enterprise with no reported revenues since
its inception. Operating expenses include those costs incurred relative to both
research and development and general administration. Operating expenses
decreased to $537,674 for the year ended December 31, 1997 from $770,830 for the
year ended December 31, 1996. The decrease of $233,156, or 30% was due primarily
to the legal fees paid in connection with an unsuccessful effort to obtain
additional financing through a sale of a significant equity portion of the
Company. Since inception, the Company has incurred total operating expenses of
$2,392,230. This amount consists primarily of expenses incurred to continue
development on the Cholestron product.
Other expense and income was a net expense of $22,169, for the year ended
December 31, 1997, as compared to a net income of $18,866 for the ended December
31, 1996. The fluctuation from an income to an additional loss component of
$41,035 or 218%, was primarily attributable to the existence in 1996 of a cost
sharing arrangement with another medical products research and development
company. This was partially offset by the interest expense which was accrued on
corporate debt.
The foregoing factors lead to the Company's net loss of $559,843 for the year
ended December 31, 1997 and $751,964 for the year ended December 31, 1996.
Liquidity and Capital Resources
From inception in August 1992, the Company has been solely dependent on funds
raised through the issuance of debt and equity securities. Additionally, the
Company has also issued shares of its common stock in exchange for goods and
services.
In both 1997 and 1996, the Company received $50,000 pursuant to the terms of two
separate convertible promissory notes. These notes contain terms which specify a
conversion to shares of common stock at a rate of $0.75 or final maturity in
November 1999 and March 2000, respectively. The Company also raised
approximately $196,000 and $45,000 through the sale of shares of its common
stock during 1997 and 1996. Proceeds raised through these financing activities
were used to support cash outflows associated with the Company's operating
activities.
As of December 31, 1997, Lifestream had no recurring source of revenue, had
incurred losses since its inception and had a working capital deficiency.
Primarily as a result of these factors, the Company's independent certified
public accountants included an explanatory paragraph in their report on the
Company's 1997 consolidated financial statements which expressed substantial
doubt about the Company's ability to continue as a going concern. Management of
the Company believes the ability of the Company to continue as a going concern
and achieve profitability is highly dependent upon numerous factors including,
but not limited to: the Company's ability to directly market and distribute its
product, Cholestron (TM) in North America; successful completion of the
Company's regulatory approval process; and the ability to provide the product at
a cost efficient price and quantity. Due to the uncertainty of these factors, it
is difficult to reliably predict when such profitability may occur, if at all.
13
<PAGE>
At December 31, 1997, the Company had a deferred tax asset of approximately
$870,000 for which management of the Company has established a 100% valuation
allowance as management cannot determine that it is more likely than not that
the Company will realize the benefit of this asset.
The development and marketing of consumer medical devices is capital intensive.
The Company has funded operations to date through private equity and debt
financing arrangements. On May 6, 1998, the Company completed a private
placement offering of shares of the Company's Common Stock, and was successful
in raising approximately $1.3 million. The Company believes the funds raised in
this offering will be sufficient to fund the current plan of operation, as
summarized below.
The Company, like most owners of computer software, will be required to modify
portions of its software so that it will function properly in the year 2000. The
Company continues to evaluate appropriate courses of corrective action,
including replacement of certain systems whose associated costs would be
recorded as assets and amortized. Accordingly, the Company does not expect the
amounts required to be expensed over the next three years to have a material
effect on its financial position or results of operations. The amount expensed
in 1997 was immaterial.
The following is management's current plan of operation for the Company:
In April 1998, the Company completed the required clinical studies for the
Cholestron(TM) unit. Upon completion of these studies, the Company immediately
filed a 510(k) notification with the Federal Drug Administration ("FDA"). This
510(k) notification process was permitted over the more lengthy Pre-Market
Application Process ("PMA") as it is the Company's position that the
Cholestron(TM) unit meets the definition of "substantially equivalent" to other
products (specifically blood glucose monitoring devices) currently being
marketed within the United States. It is the Company's belief that the FDA's
approval will be successfully obtained by July 1998.
As the Company expects regulatory approval, a pre-qualification product run of
the Cholestron(TM) unit is currently in-process. This process is performed both
in-house and through key external vendors to determine the exact assembly line
production process and to determine necessary production quality assurance
standards. Additionally, the Company is in the final stage of negotiation of a
lease agreement for a production facility in located in Post Falls, Idaho. The
Company expects to take possession of this 6,500 square foot facility during
June 1998 and immediately begin preparation for a preproduction run of 250
units, which is expected to occur during July 1998. These 250 units would be
used for beta site testing, marketing and as a final quality assurance and
control test before beginning actual production. Currently, the Company has five
full time employees, who are performing the required financial and technological
functions necessary to complete the development of the Cholestron(TM) unit. The
Company expects to increase this to approximately 15 - 20 full time equivalent
employees by August 1, 1998, which is the current anticipated date when full
production will begin.
New Accounting Pronouncements
In June 1997, the FASB issued SFAS No. 130, Reporting Comprehensive Income, and
SFAS No. 131, Disclosures about Segments of an Enterprise and Related
Information. SFAS No. 130 requires that an enterprise report, by major
components and as a single total, the change in its net assets during the period
from nonowner sources; and SFAS No. 131 establishes annual and interim reporting
standards for an enterprise's operating segments and related disclosures about
its products, services, geographic areas and major customers. Adoption of these
statements will not impact the Company's financial position, results of
operations or cash flows and any effect will be limited to the form and content
of its disclosures. Both statements are effective for fiscal years beginning
after December 15, 1997.
14
<PAGE>
The FASB recently issued SFAS 132, Employers' Disclosures about Pensions and
Other Postretirement Benefits, which amends the disclosure requirements of the
following FASB Statements: SFAS 87, Employers' Accounting for Pensions, SFAS 88,
Employers' Accounting of Settlements and Curtailments of Defined Benefit Pension
Plans and for Termination Benefits, and SFAS 106, Employers' Accounting for
Postretirement Benefits Other Than Pensions. SFAS 132 does not affect the
recognition and measurement requirements of those Statements. Adoption of this
statement will not impact the Company's financial position, results of
operations or cash flows and any effect will be limited to the form and content
of its disclosures. This statement is effective for fiscal years beginning after
December 15, 1997.
Item 7. Financial Statements.
The Company's consolidated financial statements and notes thereto appear on
pages F-1 to F-24 of this Form 10-KSB Annual Report.
15
<PAGE>
Lifestream Technologies, Inc.
and Subsidiary
(A DevelopmentStage Company)
Consolidated Financial Statements
Years Ended December 31, 1997 and 1996
F-1
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Contents
- --------------------------------------------------------------------------------
Report of Independent Certified Public Accountants 3-4
Consolidated Financial Statements:
Balance Sheets 5-6
Statements of Loss 7
Statements of Changes in Stockholders' Equity 8-11
Statements of Cash Flows 12-13
Summary of Accounting Policies 14-16
Notes to Consolidated Financial Statements 17-23
F-2
<PAGE>
Report of Independent Certified Public Accountants
To The Board of Directors of
Lifestream Technologies, Inc.
Sandpoint, Idaho
We have audited the accompanying consolidated balance sheet of Lifestream
Technologies, Inc. and Subsidiary (a development stage company), as of December
31, 1997, and the related statements of loss, changes in stockholders' equity
and cash flows for the year then ended. We have also audited the consolidated
statements of loss, stockholders' equity and cash flows for the period from
inception (August 7, 1992) through December 31, 1997, except that we did not
audit these statements (as restated) for the period from inception (August 7,
1992) through December 31, 1996; those statements were audited by another
auditor whose report, dated August 20, 1997, expressed an unqualified opinion on
those statements (as restated). These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audit.
We conducted our audit in accordance with generally accepted auditing standards.
Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the consolidated financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement
presentation. We believe that our audit provides a reasonable basis for our
opinion.
In our opinion, based on our audit and the report of another auditor, the
consolidated financial statements referred to above present fairly, in all
material respects, the consolidated financial position of Lifestream
Technologies, Inc. and Subsidiary as of December 31, 1997, and the consolidated
results of their operations and their cash flows for the year then ended and for
the period from inception (August 7, 1992) through December 31, 1997, in
conformity with generally accepted accounting principles.
The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern. As discussed in Note 1 to the
consolidated financial statements, the Company has no recurring source of
revenue, has incurred losses since inception and, at December 31, 1997, has
negative working capital. These conditions raise substantial doubt about the
Company's ability to continue as a going concern. Management's plans in regard
to these matters are also described in Note 1. The consolidated financial
statements do not include any adjustments that might result from the outcome of
this uncertainty.
Spokane, Washington /s/ BDO Seidman, LLP
February 18, 1998
F-3
<PAGE>
INDEPENDENT AUDITOR'S REPORT
----------------------------
To the Board of Directors of
Lifestream Technologies, Inc.
Sandpoint, Idaho
I have audited the consolidated statement of financial position of Lifestream
Technologies, Inc. (a Nevada corporation in the development stage), as of
December 31, 1996, and the related consolidated statements of operations,
changes in stockholders' equity and cash flows for the year ended December 31,
1996, and cumulative amounts from inception (August 7, 1992) through December
31, 1996. These consolidated financial statements are the responsibility of the
Company's management. My responsibility is to express an opinion on these
consolidated financial statements based on my audit.
I conducted by audit in accordance with generally accepted auditing standards.
Those standards require that I plan and perform the audit to obtain reasonable
assurance about whether the consolidated financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement
presentation. I believe that my audit provides a reasonable basis for my
opinion.
In my opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the consolidated financial position of
Lifestream Technologies, Inc. as of December 31, 1996, and the consolidated
results of operations, changes in stockholders' equity and cash flows for the
year ended December 31, 1996, and cumulative amounts from inception (August 7,
1992) through December 31, 1996, in conformity with generally accepted
accounting principles.
As of December 31, 1996, patent and distribution rights ($1,976,301 net of
accumulated amortization) represent 93% of total assets.
The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern. Given the facts that the
Company is in the development stage, has incurred operating losses totaling
$1,758,358 since inception, has a working capital deficiency, and is delinquent
on the payment of various notes payable (see Note 4), there is substantial doubt
about is ability to continue as a going concern (see Note 7). The consolidated
financial statements do not include any adjustments that might result from the
outcome of these financial situations.
Spokane, Washington /s/ Terrence J. Dunne, CPA
August 20, 1997
F-4
<PAGE>
<TABLE>
<CAPTION>
====================================================================================================================
December 31, 1997 1996
- --------------------------------------------------------------------------------------------------------------------
(Restated )
<S> <C> <C>
Assets (Note 1)
Current assets:
Cash $ 6,160 $ 5,229
Interest receivable, officer (Note 3) 9,482 4,019
Inventory and supplies 30,802 35,731
Prepaid expenses 2,068 27,000
- --------------------------------------------------------------------------------------------------------------------
Total current assets 48,512 71,979
- --------------------------------------------------------------------------------------------------------------------
Equipment and leasehold improvements, net of
accumulated depreciation of $18,302
and $12,216, respectively (Note 2)
23,754 16,135
- --------------------------------------------------------------------------------------------------------------------
Other assets:
Patent, net of accumulated amortization of
$493,103 and $371,339 (Note 4) 1,623,762 1,748,457
Note receivable, officer (Note 3) 69,622 54,189
Other 1,500 10,706
- --------------------------------------------------------------------------------------------------------------------
Total other assets 1,694,884 1,813,352
- --------------------------------------------------------------------------------------------------------------------
Total assets $ 1,767,150 $ 1,901,466
====================================================================================================================
</TABLE>
F-5
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Consolidated Balance Sheets
<TABLE>
<CAPTION>
====================================================================================================================
December 31, 1997 1996
- --------------------------------------------------------------------------------------------------------------------
(Restated )
<S> <C> <C>
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 216,918 $ 221,777
Interest payable 20,371 6,242
Related party payable (Note 7) 12,435 -
Notes payable (Note 5) 41,144 46,144
- --------------------------------------------------------------------------------------------------------------------
Total current liabilities 290,868 274,163
Convertible debt (Note 6) 100,000 50,000
- --------------------------------------------------------------------------------------------------------------------
Total liabilities 390,868 324,163
- --------------------------------------------------------------------------------------------------------------------
Commitments and Contingencies (Notes 5, 7, 8, 9, 10 and 11)
Stockholders' equity:
Preferred stock, $.001 par value; 5,000,000 shares
authorized; no shares issued or outstanding - -
Common stock, $.001 par value; 50,000,000 shares
authorized; 8,041,500 and 7,387,639 shares issued
and outstanding 8,041 7,387
Additional paid-in capital 3,773,536 3,415,368
Deficit accumulated during the development
stage (Note 10) (2,405,295 ) (1,845,452 )
- --------------------------------------------------------------------------------------------------------------------
Total stockholders' equity 1,376,282 1,577,303
- --------------------------------------------------------------------------------------------------------------------
Total liabilities and stockholders' equity $ 1,767,150 $ 1,901,466
====================================================================================================================
</TABLE>
See accompanying summary of accounting policies and notes to consolidated
financial statements.
F-6
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Consolidated Statements of Loss
<TABLE>
<CAPTION>
Cumulative
Amounts
from Date
of Inception
(August 7, 1992)
through Year Ended December 31,
December 31, ----------------------------------
1997 1997 1996
- --------------------------------------------------------------------------------------------------------------------
(Restated )
<S> <C> <C> <C>
Revenues $ - $ - $ -
Operating expenses:
Depreciation and amortization 511,405 130,781 127,852
Professional fees 899,323 95,527 448,866
Travel 211,160 45,430 31,073
Research and development 216,561 106,999 32,316
Salaries and wages (Note 11) 207,750 100,000 83,000
Public relations 134,740 10,746 8,300
General office 211,291 48,191 39,423
- --------------------------------------------------------------------------------------------------------------------
Total operating expenses 2,392,230 537,674 770,830
- --------------------------------------------------------------------------------------------------------------------
Loss from operations 2,392,230 537,674 770,830
- --------------------------------------------------------------------------------------------------------------------
Other (expense) income
Interest income 16,684 5,532 4,019
Interest expense (39,144) (15,067) (7,350)
Other miscellaneous (expense) income 9,395 (12,634) 22,197
- --------------------------------------------------------------------------------------------------------------------
Total other (expense) income (13,065) (22,169) 18,866
- --------------------------------------------------------------------------------------------------------------------
Net loss $ (2,405,295) $ (559,843) $ (751,964)
- --------------------------------------------------------------------------------------------------------------------
Net loss per share $ (0.07) $ (0.11)
- --------------------------------------------------------------------------------------------------------------------
Weighted average number of shares 7,831,675 7,028,113
- --------------------------------------------------------------------------------------------------------------------
</TABLE>
See accompanying summary of accounting policies and notes to consolidated
financial statements.
F-7
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Consolidated Statement of Changes in Stockholders' Equity
<TABLE>
<CAPTION>
Deficit
Accumulated
Common Stock Additional During the
--------------------------- Paid-in Developmental
Shares Amount Capital Stage Total
- ---------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Common stock issued for net assets of
prior entity at $0.21 per share 3,327,000 $ 3,327 $ 703,538 $ - $ 706,865
Common stock issued for cash at $0.83
per share 42,000 42 34,958 - 35,000
Net loss - - - (41,113) (41,113)
- ---------------------------------------------------------------------------------------------------------------------
Balances as of December 31, 1992 3,369,000 3,369 738,496 (41,113) 700,752
Common stock issued for cash at $0.83
per share 24,000 24 19,976 - 20,000
Common stock issued for services at
$0.83 per share 18,000 18 14,982 - 15,000
Common stock issued for cash at $2.97
per share 33,708 34 99,966 - 100,000
Exercise of stock options 150,000 150 - - 150
Common stock issued for services at
$2.97 per share 2,360 2 7,007 - 7,009
Common stock issued for cash at $3.00
per share 1,666 2 4,998 - 5,000
Common stock issued for patent rights
at $3.00 per share (Note 4) 470,000 470 1,409,530 - 1,410,000
Common stock issued for services at
$.54 per share 130,000 130 70,120 - 70,250
Common stock issued for services at
$.19 per share 1,266 1 245 - 246
</TABLE>
See accompanying summary of accounting policies and notes to consolidated
financial statements.
F-8
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Consolidated Statement of Changes in Stockholders' Equity
<TABLE>
<CAPTION>
Deficit
Accumulated
Common Stock Additional During the
--------------------------- Paid-in Developmental
Shares Amount Capital Stage Total
- ---------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Adjustments of outstanding shares of
common stock after reverse acquisition
(Note 1) 823,913 823 (823) - -
Net loss - - - (146,335) (146,335)
- ---------------------------------------------------------------------------------------------------------------------
Balances as of December 31, 1993 5,023,913 5,023 2,364,497 (187,448) 2,182,072
Common stock issued as a correction of
prior issue 25 - 25 - 25
Common stock issued for cash at $.358
per share 280,000 280 99,865 - 100,145
Net loss, restated (Note 12) - - - (248,200) (248,200)
- ---------------------------------------------------------------------------------------------------------------------
Balances as of December 31, 1994 (Note
12) 5,303,938 5,303 2,464,387 (435,648 ) 2,034,042
Common stock issued for services at
$.25 per share 289,500 290 72,085 - 72,375
Common stock issued for cash at $.25
per share 290,000 290 72,211 - 72,501
Common stock issued for cash at $1.00
per share 5,000 5 4,995 - 5,000
Common stock issued for reduction of
debt at $.50 per share (Note 5) 100,000 100 49,900 - 50,000
Exercise of stock options 160,000 160 - - 160
Exercise of stock options 50,000 50 6,200 - 6,250
</TABLE>
See accompanying summary of accounting policies and notes to consolidated
financial statements.
F-9
<PAGE>
<TABLE>
<CAPTION>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Consolidated Statement of Changes in Stockholders' Equity
Deficit
Accumulated
Common Stock Additional During the
--------------------------- Paid-in Developmental
Shares Amount Capital Stage Total
- ---------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Exercise of stock options 44,000 44 - - 44
Exercise of stock options 32,500 32 293 - 325
Compensatory stock options issued - - 51,375 - 51,375
Net loss, restated (Note 12) - - - (657,840) (657,840)
- ---------------------------------------------------------------------------------------------------------------------
Balances as of December 31, 1995 6,274,938 6,274 2,721,446 (1,093,488) 1,634,232
Common stock issued for services at
$.50 per share 26,350 26 13,149 - 13,175
Common stock issued for services at
$.60 per share 390,000 390 233,610 - 234,000
Common stock issued for services at
$.75 per share 12,263 12 9,185 - 9,197
Common stock issued for reduction of
debt and accrued interest at $.75 per
share 182,710 183 136,850 - 137,033
Common stock issued for cash at $.50
per share 50,000 50 24,950 - 25,000
Common stock issued for cash at $.75
per share 27,333 27 20,472 - 20,499
Common stock issued for reduction of
account payable at $.48 per share 130,000 130 62,570 - 62,700
Common stock issued for reduction of
account payable at $.50 per share 21,413 22 10,685 - 10,707
</TABLE>
See accompanying summary of accounting policies and notes to consolidated
financial statements.
F-10
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Consolidated Statement of Changes in Stockholders' Equity
<TABLE>
<CAPTION>
Deficit
Accumulated
Common Stock Additional During the
--------------------------- Paid-in Developmental
Shares Amount Capital Stage Total
- ---------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Common stock issued for reduction of
account payable at $.75 per share 22,632 23 16,951 - 16,974
Exercise stock options (Note 12) 250,000 250 31,000 - 31,250
Contributed services (Note 12) - - 83,000 - 83,000
Compensatory stock options issued
(Note 6) - - 51,500 - 51,500
Net loss, restated (Note 12) - - - (751,964) (751,964)
- ---------------------------------------------------------------------------------------------------------------------
Balances as of December 31, 1996 (Note
12) 7,387,639 7,387 3,415,368 (1,845,452) 1,577,303
Exercise of stock options 250,000 250 - - 250
Common stock issued for services at
$.75 per share 34,210 34 25,624 - 25,658
Common stock issued for cash at $.75
per share 261,333 262 195,738 - 196,000
Common stock issued for repayment of
debt and accrued interest (Note 5) 8,318 8 6,230 - 6,238
Exercise stock options 100,000 100 23,900 - 24,000
Compensatory stock options issued - - 6,676 - 6,676
Contributed services - - 100,000 - 100,000
Net loss - - - (559,843) (559,843)
- ---------------------------------------------------------------------------------------------------------------------
Balances as of December 31, 1997 8,041,500 $ 8,041 $ 3,773,536 $ (2,405,295) $ 1,376,282
- ---------------------------------------------------------------------------------------------------------------------
</TABLE>
See accompanying summary of accounting policies and notes to consolidated
financial statements.
F-11
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Consolidated Statements of Cash Flows
<TABLE>
<CAPTION>
Increase (Decrease) in Cash
Date of
Inception
(August 7, 1992)
through Year Ended December 31,
December 31, ----------------------------------
1997 1997 1996
- --------------------------------------------------------------------------------------------------------------------
(Restated)
<S> <C> <C> <C>
Cash flows from operating activities
Net loss $ (2,405,295) $ (559,843) $ (751,964)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization 511,405 130,781 126,290
Issuance of common stock for services 446,910 25,658 256,372
Issuance of compensatory stock
options for services 109,551 6,676 51,500
Contributed services 183,000 100,000 83,000
Changes in assets and liabilities:
Inventory and supplies (30,802) 4,929 -
Prepaid expenses (2,068) 24,932 3,032
Interest receivable from officer - (5,464) (4,019)
Other (10,982) 9,206 (2,000)
Accounts payable 319,734 7,576 118,276
Interest payable 28,642 15,367 6,499
- -----------------------------------------------------------------------------------------------------------------
Net cash used in operating activities (849,905) (240,182) (113,014)
- -----------------------------------------------------------------------------------------------------------------
Cash flows from investing activities
Capital expenditures (42,056) (13,705) (2,881)
Advances to officer (69,622) (15,432) (5,930)
- -----------------------------------------------------------------------------------------------------------------
Net cash used in investing activities (111,678) (29,137) (8,811)
- -----------------------------------------------------------------------------------------------------------------
</TABLE>
See accompanying summary of accounting policies and notes to consolidated
financial statements.
F-12
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Consolidated Statements of Cash Flows
<TABLE>
<CAPTION>
Increase (Decrease) in Cash
Date of
Inception
(August 7, 1992)
through Year Ended December 31,
December 31, ----------------------------------
1997 1997 1996
- --------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Cash flows from financing activities
Proceeds from issuance of convertible debt 100,000 50,000 50,000
Proceeds from exercise of stock options 62,429 24,250 31,250
Net proceeds from notes payable 226,144 - -
Proceeds from sale of common stock 579,170 196,000 45,499
- --------------------------------------------------------------------------------------------------------------------
Net cash provided by financing activities 967,743 270,250 126,749
- --------------------------------------------------------------------------------------------------------------------
Net increase in cash 6,160 931 4,924
Cash at beginning of period - 5,229 305
- --------------------------------------------------------------------------------------------------------------------
Cash at end of period $ 6,160 $ 6,160 $ 5,229
- --------------------------------------------------------------------------------------------------------------------
Supplemental schedule of non-cash investing
and financing activities
Issuance of common stock in exchange for:
Patent and distribution rights $ 2,116,865 $ - $ -
Reduction of note payable 185,000 5,000 130,000
Reduction of accrued interest 8,271 1,238 7,033
Reduction of accounts payable 90,381 - 90,381
- --------------------------------------------------------------------------------------------------------------------
Supplemental schedule of cash activities
Interest paid in cash $ - $ - $ -
- --------------------------------------------------------------------------------------------------------------------
</TABLE>
See accompanying summary of accounting policies and notes to consolidated
financial statements.
F-13
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Summary of Accounting Policies
Nature of Business Lifestream Technologies, Inc. ("Lifestream
Technologies" or "the Company") is a
development stage enterprise which holds
exclusive manufacturing and marketing rights
in the United States for the Cholestron, a
hand held instrument that measures cholesterol
levels as well as other components in blood.
The Company was incorporated pursuant to the
laws of the state of Nevada in June 1992.
Basis of Presentation The consolidated financial statements include
the operations of the Company and its wholly
owned subsidiary, Lifestream Diagnostics, Inc.
All intercompany accounts and transaction have
been eliminated upon consolidation.
Cash Equivalents For financial reporting purposes, the Company
considers all highly liquid investments
purchased with an original maturity of three
months or less to be a cash equivalent.
Financial instruments which potentially
subject the Company to a concentration of
credit risk consist of cash and cash
equivalents. Cash and cash equivalents consist
of funds deposited with various high credit
quality financial institutions.
Equipment and Leasehold Equipment and leasehold improvements are
Improvements recorded at cost. Depreciation and
amortization are provided using the
straight-line method over the useful lives or
lease term of the respective assets. Major
additions and betterments are capitalized.
Upon retirement or disposal, the cost and
related accumulated depreciation or
amortization are removed from the accounts and
any gain or loss is reflected in operations.
Patent The costs associated with acquiring patented
technology have been capitalized and are being
charged to expense using the straight line
method of amortization over seventeen years,
the estimated useful life of the patent.
In accordance with the provisions of SFAS No.
121, "Accounting for the Impairment of
Long-lived Assets and for Long-lived Assets to
be Disposed of", management of the Company
reviews the carrying value of its intangible
assets on a regular basis. Estimated
F-14
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Summary of Accounting Policies
undiscounted future cash flows from the
intangible assets are compared with the
current carrying value. Reductions to the
carrying value are recorded to the extent the
net book value of the property exceeds the
estimate of future discounted cash flows.
Income Taxes Income taxes are provided based on the
liability method of accounting pursuant to
Statement of Financial Accounting Standards
("SFAS") No. 109, "Accounting for Income
Taxes." Under this approach, deferred income
taxes are recorded to reflect the tax
consequences on future years of differences
between the tax basis of assets and
liabilities and their financial reporting
amounts at each year end. A valuation
allowance is recorded against deferred tax
assets if management does not believe the
Company has met the "more likely than not"
standard imposed by SFAS 109 to allow
recognition of such an asset.
Research and Development Research and development costs are charged to
expense as incurred.
Estimates The preparation of financial statements in
conformity with generally accepted accounting
principles requires management to make
estimates and assumptions that affect the
reported amounts of assets and liabilities and
disclosure of contingent assets and
liabilities at the dates of the financial
statements and the reported amounts of
revenues and expenses during the reporting
periods. Actual results could differ from
those estimates.
Fair Value of Financial The carrying amounts reported in the
Instruments consolidated balance sheets as of December 31,
1997 and 1996 for cash equivalents, accounts
payable and accrued expenses approximate fair
value because of the immediate or short-term
maturity of these financial instruments. The
fair value of the note receivable from an
officer cannot be determined. The fair value
of long-term debt and notes payable
approximates its carrying value as the stated
or discounted rates of the debt reflect recent
market conditions.
Stock Based Compensation SFAS No. 123, "Accounting for Stock-Based
Compensation," encourages, but does not
require, companies to record compensation
F-15
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Summary of Accounting Policies
cost for stock-based employee compensation
plans at fair value. The Company has chosen to
continue to account for stock-based
compensation using the intrinsic value method
prescribed in Accounting Principles Board
Opinion No. 25, "Accounting for Stock Issued
to Employees," and related interpretations and
to furnish the pro forma disclosures required
under SFAS No. 123, if material. Accordingly,
compensation cost for stock options is
measured as the excess, if any, of the quoted
market price of the Company's stock at the
date of the grant over the amount an employee
must pay to acquire the stock.
Net Loss Per Share In February 1997, The Financial Accounting
Standards Board ("FASB") issued SFAS No. 128,
Earnings Per Share ("EPS"). SFAS No. 128
requires dual presentation of basic EPS and
diluted EPS on the face of all income
statements issued after December 15, 1997 for
all entities with complex capital structures.
Adoption of SFAS No. 128 had no effect on the
Company's financial statements. Basic EPS is
computed as net income divided by the weighted
average number of common shares outstanding
for the period. Diluted EPS reflects the
potential dilution that could occur from
common shares issuable through stock options,
warrants and other convertible securities. As
the Company's stock options and warrants,
which cover 545,912 shares of the Company's
common stock at December 31, 1997, are
antidilutive for all periods presented only
basic EPS is presented. These securities could
potentially dilute future EPS calculations.
New Accounting In June 1997, the FASB issued SFAS No. 130,
Pronouncements Reporting Comprehensive Income, and SFAS No.
131, Disclosures about Segments of an
Enterprise and Related Information. SFAS No.
130 requires that an enterprise report, by
major components and as a single total, the
change in its net assets during the period
from nonowner sources; and SFAS No. 131
establishes annual and interim reporting
standards for an enterprise's operating
segments and related disclosures about its
products, services, geographic areas and major
customers. Adoption of these statements will
not impact the Company's financial position,
results of operations or cash flows and any
effect will be limited to the form and content
of its disclosures. Both statements are
effective for fiscal years beginning after
December 15, 1997.
F-16
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Notes to Consolidated Financial Statements
1. Development Stage The Company has been in the development stage
Operations and Going since its inception. The Company has had no
Concern recurring source of revenue, has incurred
operating losses since inception and, at
December 31, 1997, has a working capital
deficiency. These factors raise substantial
doubt about the Company's ability to continue
as a going concern. The financial statements
do not include any adjustments that may be
necessary if the Company is unable to
continue as a going concern.
Management of the Company has undertaken
certain actions to address these conditions.
These actions include seeking new sources of
capital or funding to allow the Company to
commence production of its products. The
Company anticipates commencing operations in
1998. To this end, in January 1998, the
Company entered into a license and supply
agreement with a third party manufacturer
pursuant to which the manufacturer will supply
the Company with cholesterol measurement
modules which incorporate the Company's
technology. Production will commence once the
product has been granted government approval.
There can be no assurances that the Company
will be successful in executing its plans.
2. Equipment and Leasehold Property and equipment consists of the
Improvements following:
<TABLE>
<CAPTION>
December 31, 1997 1996
-------------------------------------------------------------------------------
<S> <C> <C>
Office and data processing
equipment $ 35,146 $ 21,441
Leasehold improvements 6,910 6,910
-------------------------------------------------------------------------------
42,056 28,351
Less accumulated depreciation 18,302 12,216
-------------------------------------------------------------------------------
Property and equipment, net $ 23,754 $ 16,135
-------------------------------------------------------------------------------
</TABLE>
F-17
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Notes to Consolidated Financial Statements
3. Note Receivable - Officer The Company's president has received various
cash advances pursuant to terms of an
unsecured promissory note. Advances under the
note, which accrue interest at 8% and have no
stated maturity date, totaled $69,622 and
$54,189 at December 31, 1997 and 1996. As
repayment is not expected during 1998, the
entire balance is classified as noncurrent.
4. Intangible Assets In 1992, the Company acquired all of the
assets and liabilities of a related party
development partnership for 3,327,000 shares
of the Company's common stock. The net assets
acquired, which were recorded on the
Company's books at the historical cost basis
of the partnership, by the Company primarily
included license and distribution rights
which had been previously acquired by the
development partnership for cash of
approximately $700,000 from an unrelated
company. In 1993, the Company acquired the
patents and technology from this same
unrelated company to complete the asset
acquisition. The patents and technology were
acquired through the issuance of 470,000
shares of common stock, valued at $1,410,000.
5. Notes Payable Notes payable consist of the following:
<TABLE>
<CAPTION>
December 31, 1997 1996
-------------------------------------------------------------------------------
<S> <C> <C> <C>
Note payable to an individual (1) $ 6,000 $ 6,000
Note payable to an individual (2) - 5,000
Note payable to a corporation (3) 35,144 35,144
-------------------------------------------------------------------------------
Notes payable $ 41,144 $ 46,144
-------------------------------------------------------------------------------
</TABLE>
(1) During the year ended December 31, 1995, the
Company borrowed $6,000 from an individual
pursuant to terms of an unsecured promissory
note. The note has a stated interest rate of
prime plus two percent (10.5% at December 31,
1997). The holder was also granted warrants to
purchase 24,000 shares of the Company's common
stock at a per share price of $.001. The note
is due upon
F-18
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Notes to Consolidated Financial Statements
the Company successfully raising $100,000 or
more in either a public or private equity
offering.
(2) During the year ended December 31, 1995, the
Company borrowed $5,000 from an individual
pursuant to terms of an unsecured promissory
note. The note had a stated interest rate of
prime plus two percent. The holder was also
granted warrants to purchase 20,000 shares of
the Company's common stock at a per share
price of $.001. During the year ended December
31, 1997, the Company issued 8,318 shares of
its common stock to retire the note and
accrued interest thereon of $1,238.
(3) During the years ended December 31, 1994 and
1993, the Company was advanced $75,000 from a
corporation. During the year ended December
31, 1995, the Company retired $50,000 of this
obligation through the issuance of 100,000
shares of its common stock. The remaining
$25,000, together with accrued interest of
$10,144 was converted into an unsecured
promissory note bearing interest at 8%. The
principal balance of the note, and accrued
interest thereon, is due upon the Company
successfully completing a private or public
equity offering in which the net proceeds to
the Company exceed $500,000.
6. Convertible Debt During each of the years ended December 31,
1997 and 1996, the Company received $50,000
pursuant to the terms of two convertible
promissory notes. The promissory notes are
unsecured and bear interest at prime plus two
percent (10.5% at December 31, 1997). The
notes mature in November 1999 and March 2000,
at which time the outstanding principal and
interest are due. The holder of the notes has
the right to convert the outstanding
principal into shares of the Company's common
stock at any time prior to maturity at a per
share rate of $.75.
7. Related Party Payable At December 31, 1997, the Company has an
amount payable to an entity affiliated
through common ownership of $12,435, which is
payable on-demand.
8. Stock Options The Company has an Employee Stock Option Plan
(the "Plan") which provides for the grant of
options to purchase shares of the
F-19
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Notes to Consolidated Financial Statements
Company's common stock at exercise prices
determined by the Board of Directors. As of
December 31, 1997, all 600,000 options
originally made available under the Plan,
remain available for grant.
The Company grants from time to time stock
options to directors, vendors and others to
purchase shares of the Company's common stock
at exercise prices as determined by the chief
executive officer and approved by the Board of
Directors. These options are granted as
payment of services or as an inducement to
provide the Company funds to further develop
the product. As such, the options when granted
require the Company to recognize expenses and
an increase in additional paid-in capital.
The fair value of option grants is estimated
on the date of grant utilizing the
Black-Scholes option pricing model with the
following weighted average assumptions for
grants in 1997 and 1996, respectively:
expected life of option of four years,
expected volatility of 40%, risk-free interest
rate of 6% and a dividend yield of 0%.
The following table summarizes the stock
option activity since inception:
<TABLE>
<CAPTION>
Weighted
Average
Exercise
Shares Price
-------------------------------------------------------------------------------
<S> <C> <C>
Options outstanding at December 31, 1995 1,093,333 $ 0.21
Granted 161,834 0.09
Expired (33,333) (3.00)
Exercised (250,000) (0.13)
-----------------------------------------------------------------------------
Options outstanding at December 31, 1996 971,834 0.11
Granted 95,745 0.37
Expired (171,667) (0.11)
Exercised (350,000) (0.07)
-----------------------------------------------------------------------------
Options outstanding at December 31, 1997 545,912 $ 0.19
-----------------------------------------------------------------------------
</TABLE>
F-20
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Notes to Consolidated Financial Statements
The fair value at the date of grant of the
options granted was $6,676 and $51,500 during
the years ended December 31, 1997 and 1996.
The following table summarizes information
about outstanding options at December 31,
1997:
<TABLE>
<CAPTION>
Options Outstanding Options Exercisable
-------------------------------------- ------------------------
Weighted
Average Weighted Weighted
Range of Remaining Average Average
Exercise Number Contractual Exercise Number Exercise
Prices Outstanding Life (YRS) Price Exercisable Price
-------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
$0.001 115,000 0.28 $ 0.001 115,000 $ 0.001
$0.10-$0.15 159,412 7.05 0.11 130,000 0.10
$0.20-$0.25 220,167 4.06 0.24 171,701 0.23
$0.75 51,333 2.63 0.60 20,000 0.50
-------------------------------------------------------------------------------
$0.001-$0.75 545,912 4.00 $ 0.14 436,701 $ 0.14
-------------------------------------------------------------------------------
</TABLE>
9. Operating Lease The Company leases its office space and
certain equipment pursuant to the terms of
various operating leases expiring through
2000.
Future minimum lease payments required under
these leases is as follows:
<TABLE>
<CAPTION>
Amount
-------------------------------------------------------------------------------
<S> <C> <C>
1998 $ 9,547
1999 9,080
2000 4,242
-------------------------------------------------------------------------------
$ 22,869
-------------------------------------------------------------------------------
</TABLE>
F-21
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Notes to Consolidated Financial Statements
Rent expense for the years ended December 31,
1997 and 1996 was $10,284 and $8,047.
10. Income Taxes At December 31, 1997 and 1996, the Company had
deferred tax assets of approximately $870,000
and $690,000 principally arising from net
operating loss carryforwards for income tax
purposes. As management of the Company cannot
determine that it is more likely than not that
the Company will realize the benefit of the
deferred tax asset, a valuation allowance
equal to the deferred tax asset has been
established at both December 31, 1997 and
1996.
At December 31, 1997, the Company has net
operating loss carryforwards totaling
approximately $2,200,000 which expire in the
years 2005 through 2012.
11. Commitments and The Company entered into an employment
Contingencies agreement in March 1996 with itspresident.
This agreement is automatically extended on an
annual basis, unless terminated by either
party. The agreement calls for an annual
salary of $100,000. Further, this agreement
also provides for six months of severance pay
in the event this individual is terminated by
the Company. The officer has elected to forego
payments for services provided in 1997 and
1996. Compensation due to the officer under
this agreement in 1997 and 1996 of $100,000
and $83,000 was expensed and has been
reflected as contributed services in the
Company's financial statements.
12. Restatement of Previously In 1993, the Company acquired the distribution
Issued Financial rights to the patented technology discussed in
Statements Note 4 from a corporation for $280,000, for
which the Company recorded an intangible
asset. The purchase agreement required the
Company to pay $25,000 at closing with the
remaining $255,000 to be paid during the
F-22
<PAGE>
Lifestream Technologies, Inc. and Subsidiary
(A Development Stage Company)
Notes to Consolidated Financial Statements
subsequent two years. The Company did not make
any of the subsequent payments creating a
default under terms of the agreement. This
default caused the distribution rights to be
forfeited back to the seller. The Company did
not previously record this default and
continued to amortize the intangible asset.
The Company also did not previously record
compensation expense in 1996 for services
contributed to it pursuant to the terms of the
employment agreement discussed in Note 11.
Also in 1996 an error was made in recording
the exercise of stock options.
The financial statements of prior years have
been restated to reflect the correction of
these errors as follows:
<TABLE>
<CAPTION>
Year Ended December 31,
-------------------------------------------
1994 1995 1996
-----------------------------------------------------------------------------
<S> <C> <C> <C>
Loss, as previously
reported $ (225,946) $ (674,310) $ (670,654)
Write-off and
amortization of intangible
asset (22,254) 16,470 32,690
Contributed services (83,000)
Exercise of stock option (31,000)
----------------------------------------------------------------------------
Loss, as restated $ (248,200) $ (657,840) $ (751,964)
----------------------------------------------------------------------------
</TABLE>
These errors had no impact on previously
reported loss per share amounts.
F-23
<PAGE>
Item 8. Change In and Disagreements with Accountants on Accounting and
Financial Disclosure
On November 15, 1997 Lifestream Technologies, Inc. (the "Registrant" or the
"Company") dismissed the accounting firm of Terrence J. Dunne, CPA ("Mr. Dunne")
as the Company's independent accountant. The Board of Director's decision to
change independent accounting firms was the result of a mutually agreeable
decision between the Registrant and Mr. Dunne to discontinue their relationship,
which resulted in Mr. Dunne submitting a resignation letter to the Registrant,
that was received on November 15, 1997. The Registrant solicited a formal
proposal from BDO Seidman, LLP ("BDO") due to BDO's reputation and expertise in
the medical products manufacturing industry.
During the two most recent fiscal years and the subsequent interim period prior
to December 5, 1997, there have been no disagreements with Mr. Dunne on any
matter of accounting principles or practices, financial statement disclosure, or
auditing scope or procedure or any reportable events. Mr. Dunne's report on the
consolidated financial statements of the Company for the past two years
contained an explanatory paragraph relative to a going concern uncertainty.
There were no limitations on the scope of the opinion or on the work performed.
The Registrant provided the above disclosure to Mr. Dunne, and requested that he
furnish the Registrant with a letter addressed to the Securities and Exchange
Commission (the "SEC") stating whether he agreed with the above statements. Mr.
Dunne in his letter dated May 4, 1998, stated that he did in fact agree with the
statements made herein.
The Registrant engaged BDO effective December 5, 1997. During the years ended
December 31, 1997 and 1996, the Registrant did not consult with BDO regarding:
(I) the application of accounting principles to a specified transaction; (ii)
the type of opinion that might be rendered on the Registrant's financial
statements; or (iii) any matter that was the subject of a disagreement with the
Registrant's former accountant or a reportable event (as contemplated by Item
304 of Regulation S-B)
The Registrant provided BDO with a copy of the 8-K, and requested that BDO
review such report before it was filed with the SEC and had given BDO the
opportunity to furnish the Registrant with a letter addressed to the SEC
containing any new information, clarification or statement as to whether they
agreed with the statements made by the Registrant regarding Lifestream
Technologies, Inc.'s relationship with BDO.
16
<PAGE>
PART III.
Item 9. Directors, Executive Officers, Promoters and Control Persons;
Compliance with Section 16(a) of the Exchange Act.
The current executive officers, directors and significant employees of the
Company are as follows:
Name Age Position
---- --- --------
Christopher Maus 45 President, CEO & Director
Robert F. Boyle, CPA 54 Secretary and Treasurer
Terrence Schreier 50 Chairman of the Board
David Klausmeyer 67 Director
William Gridley 58 Director
Each director is elected to hold office for a two year term or until the next
annual meeting of stockholders and until his successor is elected and qualified.
The officers of the Company serve at the pleasure of the Company's Board of
Directors.
The following sets forth certain biographical information with respect to the
directors and executive officers of the company.
Christopher Maus brings significant experience in marketing and distribution
leadership for start-up ventures in the consumer health and beauty industry. In
the past, he managed the manufacture and international sales for eight different
products in a medical industry niche market. His Solaire Cosmetic Device company
grew to $12 million in sales in 18 months. In addition to coordinating
development of the Cholestron device, gathering and managing a team of top
development and management professionals, he facilitated the raising of
approximately $4 million for the formation of the company. He has been a
Director, President and Chief Executive Officer of the Company since its
reorganization in February of 1994. From 1989 to 1994, Mr. Maus was a partner in
the Lifestream Development Partnership engaged in product research and
development and various pre-marketing and pre-production actions necessary to
establish the basis for the Cholestron device.
Robert F. Boyle joined the Company in April of 1996 as its secretary/treasurer.
Mr. Boyle is a Certified Public Accountant and Member of the AICPA Society for
over thirty years. Recently, Mr. Boyle sold his interest in a large regional
public accounting practice located in Northern California. Prior to this sale,
Mr. Boyle was partner in charge, where his numerous duties included the
management of the practice and personnel, client development and performance and
review of accounting and tax services. Mr. Boyle graduated from San Diego State
University in 1967.
17
<PAGE>
W. Terry Schreier brings a broad base of experience through numerous business
endeavors. Mr. Schreier began his career (practice) with a legal firm in Kansas
with an emphasis in corporate finance, health care and security law. He joined
Marion Laboratories, Inc. in 1978 as senior corporate counsel with major
responsibilities for corporate and financial development. Mr. Schreier has been
CEO for a number of public companies including Continental Healthcare Systems,
Inc., in 1985, Cell Technology, Inc., in 1991, Air Methods Corporation, in 1994,
and has been the Managing Director for Transition Partners, Ltd. since 1994. Mr.
Schreier has a M.B.A. in finance and J.D. in corporate and security law. Mr.
Schreier has been Chairman of the Board of Directors since October of 1995.
David Klausmeyer has been President and Director of Nanodynamics,Inc., a
privately held company engaged in scientific instrument development, since 1989.
He is a managing partner of Southwest Reification Ventures Group, Houston, a
venture capital consulting firm. Additionally, since 1993 he has served as
co-chairman and U. S. Representative of G. H. Securities Ltd., a broker-dealer
firm engaged in the securities business outside of the United States. Klausmeyer
also currently serves on the Board of Directors of numerous companies including,
Imaging Products, Inc., a firm engaged in rare isotope research, and TWK
Technologies, Inc., an advanced semi-conductor development firms. He serves on
the advisory board for Onasco Companies, a diagnostic kit manufacturing company.
In the past he has served in an executive capacity and as director with numerous
public and private companies. Klausmeyer has been involved in numerous
financing, mergers and joint ventures during his 35 year career in corporate
finance. He received a BSS degree from Georgetown University and has been a
Director of the Company since February of 1994.
William Gridley is president of Kingston Technologies, a medical products
company with merchandise for wound and skin care, cardiology, radiology and
ophthalmology. His extensive financial background in investment management and
development includes serving in the past as president for several companies,
among them Brandywine Investors, Ind., Crescent Diversified, Ltd. and Competrol
BVI. Additionally, Mr. Gridley held the post of Executive Vice President of
American Express Bank for six years, and Vice president of Chase Manhattan Bank
for eleven years. He is currently Vice Chairman and Chairman of the Finance
Committee at Tuskegee University, a position he has held since 1980. Mr. Gridley
earned a BA from Yale University. William Gridley has been a Board Member since
February of 1996.
18
<PAGE>
Item 10. Executive Compensation.
Cash Compensation
Below is the aggregate annual remuneration of each of the highest paid persons
who are officers or directors of the Company during the Company's last two years
ended December 31, 1997 and 1996.
<TABLE>
<CAPTION>
Summary Compensation Table
Other Annual
Name and Principal Position Year Salary Bonus Compensation
- ----------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Christopher Maus 1997 $100,000(1) $0 $0
President, CEO, Director 1996 $ 83,000(1) $0 $0
1995 $ 0(2) $0 $0
</TABLE>
1. In March 1996, the Company executed an employment contract with Mr. Maus
(see employment agreements below). As such Mr. Maus was entitled to a
salary of $100,000 per year. Mr. Maus elected to waive the salary for both
years (expense was recorded with an offset to contributed capital)
2. No compensation was paid to Mr. Maus in 1995 due to his limited involvement
in Company matters. The Company did not impute an salary as such an amount
was determined to be immaterial.
Employment Agreements
The Company executed an employment agreement with its Chief Executive Officer in
March 1996. The agreement was established to annually renew if not terminated by
either party. The agreement states an salary of $100,000 per year and includes
six months of severance pay in the event of termination.
Option/SAR Grants in The last Fiscal Year
- -----------------------------------------
For the year ended December 31, 1997, there were no option or SAR grants to the
Chief Executive Officer.
Aggregated Option Exercises in Last Fiscal Year and
1997 Fiscal Year End Option Values
<TABLE>
<CAPTION>
Shares Number of Unexercised Value of Unexercised
Acquired on Options at FY-End In the Money Options
Name Exercise Value Realized Exercisable Unexercisable Exercisable Unexercisable
- ---- -------- -------------- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
Christopher Maus 250,000 $82,250 -0- -0- -0- -0-
</TABLE>
Stock Option Plan
The Company has reserved 600,000 shares of its Common Stock for issuance upon
the exercise of options to be granted or available for grant under an Incentive
Stock Option Plan ("ISOP"). Options granted under the ISOP fall within the
meaning and conform to Section 422 of the Internal Revenue Code of 1986, as
amended (the "Code"). Under the terms of the ISOP, all officers, employees,
consultants, and advisors of the Company will be eligible for ISOs. The Board of
Directors will determine in its discretion which persons will receive ISOs, the
applicable vesting provisions, and the exercise term thereof. The terms and
conditions of each option grant may differ and will be set forth in the
optionee's individual incentive stock option agreement. The Company has
currently not issued any shares under the ISOP.
19
<PAGE>
Item 11. Security Ownership of Certain Beneficial Owners and Management.
The following table sets forth certain information regarding beneficial
ownership of the Company's Common Stock as of May 4, 1998 (a) by each person
known to the Company to own beneficially or more than 5% of any class of the
Company's securities, including those shares subject to outstanding options and
(b) by each of the Company's Officers and Directors and (c) by all officers and
directors of the company as a group. As of May 4, 1998, there were 8,502,829
shares of Common Stock of the Company issued and outstanding. Except as
otherwise set forth, the address of each of the individuals described below is
515 Pine St., Suite 200, Sandpoint, Idaho 83864.
<TABLE>
<CAPTION>
Name and address of Owner Shares Beneficially Owned Percent of Class
- ------------------------- ------------------------- ----------------
<S> <C> <C>
Christopher Maus 1,902,700 22.38%
President , Chief Executive Officer & Director
Robert F. Boyle, CPA 96,667 1.14%
Secretary and Treasurer
W. Terry Schreier 328,333 3.86%
Chairman of the Board
1942 Broadway, Suite 303
Boulder, CO. 80302
David Klausmeyer 70,000 .82%
Director
288 Litchfield Lane,
Houston, TX. 77024
William Gridley 29,167 .34%
Director
405 Park Ave., 4th floor
NY., NY. 10022
-------- ------
All Officers and Directors as a Group 2,426,867 28.54%
========= ======
(5 persons)
Tim Mathers 1,140,000 13.40%
4901 S. Franklin St.
Eaglewood, CO 80110
Michael Stranahan 739,500 8.70%
132 W. Second St., Suite A
Perrysburg OH 43551
</TABLE>
20
<PAGE>
Item 12. Certain Relationships and Related Transactions.
The President of the Company has received various cash advances which were
formalized into a note receivable on December 31, 1995. The note bears interest
at 8% per annum until paid and is due on demand. The note receivable balance at
December 31, 1997 and 1996, respectively, was $69,622 and $54,189.
21
<PAGE>
Item 13. Exhibits and Reports on Form 8-K
1. Exhibit 27 - Financial Data Schedule
22
<PAGE>
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant has
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
LIFESTREAM TECHNOLOGIES, INC.
BY: /s/ Christopher Maus
------------------------------------------------------------------
Christopher Maus, President, Chief Executive Officer, and Director
DATE: May 13, 1998
BY: /s/ William Gridley
------------------------------------------------------------------
William Gridley, Director
DATE: May 13, 1998
BY: /s/ Robert F. Boyle
-----------------------------------------------------------------
Robert F. Boyle, Secretary and Treasurer
DATE: May 13, 1998
23
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
audited financial statement of the Company for the year ended December 31, 1997,
and should be read in conjunction with, and is qualified in its entirety by,
such audited financial statements.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> DEC-31-1997
<CASH> 6,160
<SECURITIES> 0
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 30,802
<CURRENT-ASSETS> 48,512
<PP&E> 23,754
<DEPRECIATION> 18,302
<TOTAL-ASSETS> 1,767,150
<CURRENT-LIABILITIES> 290,868
<BONDS> 0
0
0
<COMMON> 8,041
<OTHER-SE> 1,368,241
<TOTAL-LIABILITY-AND-EQUITY> 1,767,150
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 537,674
<OTHER-EXPENSES> 12,634
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 15,067
<INCOME-PRETAX> 0
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (559,843)
<EPS-PRIMARY> (0.07)
<EPS-DILUTED> 0
</TABLE>
